Takeda will pay Insilico to use its proprietary Pharma.AI platform to advance drug candidates across several therapeutic ...

On July 2, 2026, Insilico Medicine announced a collaboration with Takeda to apply its Pharma.AI platform to discover drug ...

The deal could include further milestone payments, potentially bringing the total value to approximately $600m.

Alex Zhavoronkov, Founder, CEO & CBO of Insilico Medicine, says the Takeda deal lets the company scale beyond its own ...

Hong Kong-listed Insilico Medicine on Thursday announced a partnership with Japanese drugmaker Takeda (TAK) to discover, ...

The company is targeting a return on equity of at least 5% over that time, Julie Kim said at her first news conference after ...

Detailed price information for Takeda Pharmaceutical Co. Ltd (TKPHF) from The Globe and Mail including charting and trades.

Bristol-Myers (BMY) stock is in focus as a psoriasis therapy from Takeda (TAK) outperforms the company's FDA approved therapy Sotyktu in a late-stage trial. Read more here.

Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest.  | Insilico Medicine has signed ...

View Takeda Pharmaceutical Co. Ltd. Sponsored ADR TAK stock quote prices, financial information, real-time forecasts, and company news from CNN.

Takeda ( TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily ...

Editor’s note: This story was updated June 12, 2026 to include comment from Takeda. It was also updated at 8:40 a.m. on June 13, 2026 to clarify that layoffs could start as soon as July and that the ...